INTS

Business Context and Reporting Period

Company: Intensity Therapeutics, Inc. (INTS)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Intensity is a late-stage clinical biotechnology company developing INT230-6, an intratumoral (IT) therapy for solid tumors. The product combines cisplatin and vinblastine sulfate with a proprietary amphiphilic molecule (SHAO) to enhance drug dispersion within tumors. The company has no commercial revenue and relies on capital raises to fund operations.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. The company reported no debt as of December 31, 2024, having converted all prior convertible notes to equity during its 2023 IPO.

Material Changes vs. Prior Period

• Operating Expenses: Increased 100% year-over-year, driven primarily by a $5.7 million increase in Research and Development (R&D) expenses. This was largely due to the initiation of the Phase 3 INVINCIBLE-3 study (Sarcoma) and the Phase 2 INVINCIBLE-4 study (Breast Cancer).
• Net Loss: Widened by $5.7 million to $16.3 million, reflecting the surge in clinical trial costs and increased General and Administrative (G&A) expenses associated with public company compliance.
• Liquidity: Cash reserves declined by approximately $6.0 million. The company utilized cash for operating activities and invested in marketable securities in 2023, which were redeemed in 2024.
• Financing: In late 2024, the company raised approximately $3.0 million via a registered direct offering and $0.2 million via an At-The-Market (ATM) program to extend its runway.

Guidance, Outlook, and Risks

Clinical Pipeline Progress

• INVINCIBLE-3 (Phase 3 Sarcoma): Initiated in July 2024; enrolling 333 patients across 8 countries. Primary endpoint is overall survival.
• INVINCIBLE-4 (Phase 2 TNBC): Initiated in October 2024; enrolling 54 patients. Primary endpoint is pathological complete response (pCR).
• INVINCIBLE-2 (Phase 2 Breast): Database locked in November 2023; data showed high tumor necrosis rates (up to 95%) and favorable safety.

Management Commentary & Outlook

Management projects that current cash reserves ($2.6 million) are sufficient to fund operations only through the end of the first quarter of 2025. The company explicitly states it will need to raise substantial additional funding to continue clinical trials and operations. Failure to secure financing could force delays or termination of development programs.

Risks and Contingencies

• Going Concern: The independent auditor has issued a report expressing "substantial doubt" about the company's ability to continue as a going concern due to recurring losses and negative cash flows.
• Capital Requirements: The company has no committed external funding sources. Future equity raises may result in significant dilution to existing shareholders.
• Regulatory & Clinical Risk: Success depends entirely on the approval of INT230-6. The company has no approved products and faces risks related to clinical trial outcomes, patient enrollment, and FDA regulatory approval.
• Manufacturing: The company relies on third-party contract manufacturers for all production, creating supply chain dependencies.

Investor Verification Checklist

• Cash Runway: Verify the exact date cash reserves are projected to be exhausted (management states end of Q1 2025) and the status of any new financing efforts.
• Capital Raise Terms: Review the terms of the November 2024 registered direct offering and ATM program for dilution impact and warrant exercise prices.
• Clinical Enrollment Rates: Monitor enrollment progress for the INVINCIBLE-3 and INVINCIBLE-4 studies to ensure they meet the projected timelines (completion expected in 2026).
• Internal Controls: Note that material weaknesses in internal controls identified in 2023 were remediated as of December 31, 2024; verify ongoing effectiveness in future filings.
• Patent Status: Confirm the status of patents in Russia and Israel, which are noted as being in regions with military conflict, potentially affecting IP protection.